Michael Craig, MD
Hematology & Oncology · Morgantown, WVNPI 1801999750
Payments from drug & device makers
Across 213 payments — averaging $6482.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$1.1M
- Bristol Myers Squibb$156K
- Takeda Pharmaceuticals U.S.A., Inc.$42K
- Janssen Research & Development, LLC$25K
- Otsuka Pharmaceutical Co., Ltd.$22K
- Daiichi Sankyo Inc.$19K
- plus $36K from 32 others
Across 2 payments — averaging $2345.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$5K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 21 | $1,080,949 |
| Bristol Myers Squibb | 20 | $155,868 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $41,527 |
| Janssen Research & Development, LLC | 9 | $25,253 |
| Otsuka Pharmaceutical Co., Ltd. | 7 | $21,969 |
| Daiichi Sankyo Inc. | 10 | $19,165 |
| Acerta Pharma LLC | 2 | $7,862 |
| E.r. Squibb & Sons, L.L.C. | 15 | $7,277 |
| AstraZeneca | 17 | $6,661 |
| Puma Biotechnology, Inc. | 1 | $3,700 |
| Novartis | 23 | $3,518 |
| Secura Bio, Inc. | 3 | $2,100 |
| Genentech, Inc. | 3 | $1,701 |
| Merck | 4 | $1,276 |
| Johnson & Johnson | 4 | $296 |
| Pfizer | 11 | $199 |
| Astellas Pharma US Inc | 6 | $164 |
| Geron Corporation | 1 | $135 |
| Amgen | 1 | $125 |
| Tempus AI, Inc | 6 | $118 |
| Incyte Corporation | 4 | $86 |
| Genentech USA, Inc. | 4 | $83 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Array Biopharma Inc | 4 | $68 |
| Eisai Inc. | 3 | $68 |
| AbbVie | 3 | $66 |
| Regeneron Healthcare Solutions, Inc. | 3 | $59 |
| Galvanize Therapeutics, Inc | 1 | $53 |
| Acrotech Biopharma Inc. | 3 | $42 |
| Gilead | 2 | $40 |
| Novocure Inc. | 2 | $40 |
| Bayer | 2 | $31 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $30 |
| Invivyd Inc | 1 | $22 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Sanofi | 1 | $18 |
| ADC Therapeutics America, Inc. | 1 | $15 |
| AVEO Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$1,380,697 in reported general payments places this provider in the 95th percentile of 72 hematology & oncology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Morgantown
- Ashkan EmadiMorgantown$8.7M
- Lauren VeltriMorgantown$1.4M
- Jame AbrahamMorgantown$944K
- Abraham KanateMorgantown$833K
- Joanna KolodneyMorgantown$657K
- Salah Ud Din SafiMorgantown$557K
- Sobha KurianMorgantown$544K
- Konstantinos SdrimasMorgantown$149K
- Shalu PahujaMorgantown$122K
- Sidra NajeebMorgantown$118K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.